The addition of hs-cTnI to a clinical risk factor model (including age ≥75, prior HF, type 2 diabetes mellitus, number of vascular beds with atherosclerotic disease, body-mass index, anemia, chronic kidney disease, and hypertension) contributed very little to the predictive performance (C-index 0.90 vs. 0.88, p < 0.001) [27]. This evidence concerns the gene TNNI3 and chronic kidney disease.